This result was consolidated by recent findings indicating that increased SPP1 expression was associated with a poor outcome for patients with lung and breast cancers and promoted drug resistance and EMT transition in prostate cancer [72,73]. This evidence concerns the gene SPP1 and prostate carcinoma.